Investment

Archangels sees investment activity ‘picking up’

David Ovens
David Ovens: successful year

Investment syndicate Archangels expects activity to pick up in 2025 after a “busy year” in a “difficult investment environment”.

The Edinburgh-based company led investment of £27.3 million into Scotland’s early-stage tech and life science companies during 2024.

Of that total, £13.8m came directly from Archangels’ members, a small increase on Archangels’ investment activity in 2023 (£13.4m). Archangels also returned around £12.5m to investors through exit related income and dividends.

David Ovens, joint managing director at Archangels, said: “In line with previous years, 2024 has proved to be another very busy and successful year for Archangels.

“Despite operating within a very difficult investment environment, we are particularly pleased to have participated in three major Series A funding rounds for portfolio companies, all of which are now well set to achieve their scaling ambitions.

“While the M&A market for early-stage companies, just like the investment environment, has remained challenging, there are signs heading into 2025 that activity is picking up.”

The year saw Archangels add Bead BioPharma to its portfolio through an oversubscribed £900,000 funding round. 

The syndicate made several key follow-on investments to support the scaling of its portfolio companies, including three major series A funding rounds together totalling £18m, including:

* Biotech firm Calcivis, which secured £5m to roll-out its cutting-edge dental technology;

* Nanomaterial producer iGii, which raised £8.8m to accelerate growth and scale manufacturing capability

* Training software management platform Administrate, which raised £3.05m to expand its market reach.

Other external funding rounds included:

* Biotech company Cytomos which recently raised £5m to scale up production of its cell analysis technology

* Drug formulation and clinical trials company BDD Pharma which raised £2m to support; expansion and the opening of a new lab facility in Glasgow. 

Co-investors on deals during 2024 included Investment Fund for Scotland (managed by Maven Capital), Scottish National Investment Bank, Old College Capital, Scottish Enterprise, Par Equity, Mercia and various Scottish angel syndicates.



Leave a Reply

Your email address will not be published. Required fields are marked as *

This site uses Akismet to reduce spam. Learn how your comment data is processed.